Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
QuintilesIMS
Express Scripts
Boehringer Ingelheim
Farmers Insurance
Teva
McKesson
Johnson and Johnson
US Department of Justice

Generated: July 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,947,724

« Back to Dashboard

Which drugs does patent 7,947,724 protect, and when does it expire?

Patent 7,947,724 protects ALOXI and is included in one NDA.

Protection for ALOXI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty patent family members in forty countries.
Summary for Patent: 7,947,724
Title:Liquid pharmaceutical formulations of palonosetron
Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
Inventor(s): Calderari; Giorgio (Rancate, CH), Bonadeo; Daniele (Varese, IT), Cannella; Roberta (Varese, IT), Braglia; Enrico (Pazzallo, CH), Braglia; Riccardo (Pazzallo, CH), Miksztal; Andrew (Palo Alto, CA), Malefyt; Thomas (Carmel Valley, CA), Lee; Kathleen M. (Palo Alto, CA)
Assignee: Helsinn Healthcare S.A. (Lugano, CH) Roche Palo Alto LLC (Palo Alto, CA)
Application Number:11/186,311
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,947,724
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound;

Drugs Protected by US Patent 7,947,724

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Helsinn Hlthcare ALOXI palonosetron hydrochloride INJECTABLE;INTRAVENOUS 021372-002 Feb 29, 2008 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Helsinn Hlthcare ALOXI palonosetron hydrochloride INJECTABLE;INTRAVENOUS 021372-001 Jul 25, 2003 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,947,724

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,457,020 Liquid pharmaceutical formulations of palonosetron ➤ Sign Up
8,598,219 Liquid pharmaceutical formulations of palonosetron ➤ Sign Up
8,729,094 Liquid pharmaceutical formulations of palonosetron ➤ Sign Up
7,947,725 Liquid pharmaceutical formulations of palonosetron ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,947,724

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 2110 ➤ Sign Up
Argentina 042977 ➤ Sign Up
Austria 410167 ➤ Sign Up
Australia 2004208505 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Accenture
Boehringer Ingelheim
US Army
McKinsey
Julphar
Queensland Health
Harvard Business School
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.